论文部分内容阅读
目的:探讨卡介苗多糖核酸(BCGPSN)诱导变应性鼻炎患者结核菌素皮试(PPD)阳转情况及其治疗变应性鼻炎的相关机制。方法:将60例变应性鼻炎患者,随机分为BCGPSN治疗组和口服息斯敏组,各30例。正常对照组20例。应用酶联免疫吸附试验和UniCAP系统检测治疗前后血清嗜酸粒细胞阳离子蛋白(ECP)、血清总IgE(tIgE)水平,同时观察PPD。结果:BCGPSN治疗组治疗后,ECP、tIgE明显低于治疗前,差异有统计学意义(P<0.01),PPD阳转率为37.5%,与息斯敏组比较差异有统计学意义(P<0.01)。结论:BCGPSN可调节变应性鼻炎患者的免疫失衡,促进Th1细胞功能,减轻变应性鼻炎的发作。
Objective: To investigate the positive reaction of tuberculin skin test (PPD) in patients with allergic rhinitis induced by BCGPSN and its related mechanism in the treatment of allergic rhinitis. Methods: Sixty patients with allergic rhinitis were randomly divided into BCGPSN treatment group and oral astemizole group, 30 cases in each group. Normal control group of 20 cases. Serum eosinophil cationic protein (ECP) and total serum IgE (t IgE) levels were measured by enzyme-linked immunosorbent assay (ELISA) and UniCAP system before and after treatment. PPD was also observed. Results: The levels of ECP and tIgE in BCGPSN treatment group were significantly lower than those before treatment (P <0.01), and the positive rate of PPD was 37.5%, which was significantly different from that in the asbestos group (P < 0.01). CONCLUSION: BCGPSN can regulate immune imbalance in patients with allergic rhinitis, promote Th1 cell function and reduce the incidence of allergic rhinitis.